Pipeline — registered trials by phase
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
— · Relapsing Multiple Sclerosis, Multiple Sclerosis · Recruiting · est. 2032-04-01
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
— · Relapsing Multiple Sclerosis · Active Not Recruiting · est. 2026-10-31
Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel
— · B-cell Mediated Autoimmune Disorders · Not Yet Recruiting · est. 2039-12-01
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
— · Multiple Sclerosis · Recruiting · est. 2035-03-31
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
— · Pancreatic Cancer, Colorectal Cancer, Rectal Cancer · Completed · est. 2018-08
Study of TG-1801 in Subjects With B-Cell Lymphoma
— · B-Cell Lymphoma · Completed · est. 2024-02-21
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
— · Chronic Lymphocytic Leukemia, Richter Syndrome · Completed · est. 2021-11-04
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
— · B-cell Mediated Autoimmune Disorders · Recruiting · est. 2026-12-01
TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
— · Chronic Lymphocytic Leukemia · Completed · est. 2017-11
Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
— · Hodgkin's Lymphoma · Completed · est. 2016-05
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
— · Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma · Completed · est. 2019-10
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
— · Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma · Completed · est. 2018-02
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
— · Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Non Follicular Indolent Non-Hodgkin Lymphoma · Completed · est. 2022-02-15
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
— · Schizophrenia · Recruiting · est. 2028-12-12
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
— · Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia · Completed · est. 2015-05
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
— · Multiple Sclerosis · Recruiting · est. 2027-07-31
Ublituximab + Ibrutinib in Select B-cell Malignancies
— · Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma · Completed · est. 2015-12
An Extension of the TG1101-RMS201 Trial
— · Relapsing Remitting Multiple Sclerosis · Completed · est. 2022-11-11
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
— · Myasthenia Gravis · Recruiting · est. 2028-07-01
Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis
— · Multiple Sclerosis · Completed · est. 2017-09-27
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
— · Relapsing Multiple Sclerosis (RMS) · Active Not Recruiting · est. 2032-05-31
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
— · Relapsing Multiple Sclerosis (RMS) · Completed · est. 2020-07-23
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
— · Relapsing Multiple Sclerosis · Active Not Recruiting · est. 2026-10-31
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
— · Chronic Lymphocytic Leukemia · Completed · est. 2020-04-01
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
— · Relapsing Multiple Sclerosis · Recruiting · est. 2030-01-01
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
— · Relapsing Multiple Sclerosis (RMS) · Completed · est. 2020-08-04
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
— · Relapsing Multiple Sclerosis · Recruiting · est. 2027-01-21
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where TG Therapeutics is lead sponsor; 27 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 10-Q2026-08-05Quarterly report
- 8-K2026-08-03Current report (material event)
- 8-K2026-06-12Current report (material event)
- 8-K2026-06-03Current report (material event)
- 8-K2026-05-27Current report (material event)
- 10-Q2026-05-06Quarterly report
- 8-K2026-05-06Current report (material event)
- DEF 14A2026-04-30Proxy statement
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- 8-K2026-03-20Current report (material event)
- 10-K2026-02-27Annual report
- 8-K2026-02-26Current report (material event)
- 8-K2026-01-13Current report (material event)
- SCHEDULE 13G2025-11-10SCHEDULE 13G
- 10-Q2025-11-05Quarterly report
- 8-K2025-11-03Current report (material event)
- S-82025-08-08Employee stock plan
- S-3ASR2025-08-08S-3ASR
- 10-Q2025-08-08Quarterly report
- 8-K2025-08-04Current report (material event)
- 8-K2025-06-13Current report (material event)
- SCHEDULE 13G2025-05-13SCHEDULE 13G
- 10-Q2025-05-09Quarterly report
- 8-K2025-05-05Current report (material event)
- ARS2025-04-30Annual report to holders
- DEFA14A2025-04-30DEFA14A
- DEF 14A2025-04-30Proxy statement
- SCHEDULE 13G/A2025-04-30SCHEDULE 13G/A
- PRE 14A2025-04-18PRE 14A
- 10-K2025-03-03Annual report
- 8-K2025-03-03Current report (material event)
- 8-K2025-01-14Current report (material event)
- SCHEDULE 13G/A2025-01-08SCHEDULE 13G/A
- SC 13G/A2024-11-14Large holder update
- 10-Q2024-11-07Quarterly report
- 8-K2024-11-04Current report (material event)
- SC 13G/A2024-10-07Large holder update
- 10-Q2024-08-09Quarterly report
- 10-K/A2024-08-09Annual report (amended)
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.